-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Panobinostat

Program: Special-Interest Sessions
Session: Special Education Session on Clinical Applications of Newly Approved Drugs
Saturday, December 5, 2015, 9:30 AM-11:00 AM
Tangerine 2 (WF2), Level 2 (Orange County Convention Center)

Sagar Lonial, MD

Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA; Winship Cancer Institute of Emory University, Department of Hematology and Medical Oncology, Atlanta, GA

Disclosures: Lonial: Onyx: Consultancy , Research Funding ; Novartis: Consultancy , Research Funding ; Celgene: Consultancy , Research Funding ; Janssen: Consultancy , Research Funding ; Bristol-Myers Squibb: Consultancy , Research Funding ; Millennium: Consultancy , Research Funding . Off Label Use: ACY 1215, vorinostat, panobinostat for myeloma.

See more of: Special Education Session on Clinical Applications of Newly Approved Drugs
See more of: Special-Interest Sessions
<< Previous Presentation | Next Presentation